Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

NCT ID: NCT04133337

Last Updated: 2019-10-21

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-11-01
• Study Completion Date: 2021-06-30

Brief Summary

The aim of this study was to investigate the safety and efficacy of SHR-1210 in combination with the anti-vascular survival target drug apatinib in patients with resectable NSCLC, and to provide new treatment options for neoadjuvant therapy in patients with the period IB-IIIA NSCLC.

Conditions

Lung Diseases; Neoplasms; Respiratory Tract Diseases; Thoracic Neoplasms; Non-small-cell Lung Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Apatinib Combined With SHR-1210 Injection

• Drugs:Apatinib Apatinib mesylate tablets 250 mg qd po, discontinued one week before surgery.
• Drugs: SHR-1210 SHR-1210 injection 200mg (5mL), ivgtt, q2w, 3 cycles, each time 20-60min completed infusion.
• Surgery:

The patient underwent imaging examinations within 7 days prior to surgery, including chest CT and related metastatic examinations. The patient underwent surgery 7-8 weeks after the first dose.

Group Type: EXPERIMENTAL

Apatinib

Intervention Type: DRUG

Apatinib Mesylate Tablets

SHR-1210

Intervention Type: DRUG

Camrelizumab for Injection

Interventions

Apatinib

Apatinib Mesylate Tablets

Intervention Type: DRUG

SHR-1210

Camrelizumab for Injection

Intervention Type: DRUG

Other Intervention Names

AiTan; H20140103; Camrelizumab; Karuilizhu Dankang; S20190027

Eligibility Criteria

Inclusion Criteria

• 1. Age: 18 years old to 75 years old, male or female;
• 2. Initial treatment of patients with IB-IIIA non-small cell lung cancer who are expected to be surgically resected;
• 3. Histopathologically confirmed non-small cell lung cancer with measurable tumor lesions (spiral CT scan≥10mm, meeting RECIST 1.1 criteria);
• 4. ECOG PS: 0-1 points
• 5. The function of important organs meets the following requirements (no blood components and cell growth factors are allowed for 2 weeks before the start of study): Absolute neutrophil count (ANC)≥1.5×10 E+9/L; platelets≥100×10E+9/L / L; hemoglobin ≥9g/dL; serum albumin(ALB)≥2.8g/dL; a total bilirubin (TBil) of≤1.5 ULN, ALT and AST≤2.5 ULN, in case of liver metastasis, ALT and AST≤5 ULN; creatinine clearance rate≥ 50mL/min(Cockcroft-Gault);thyroid function is normal.
• 6. Estimated survival time≥3 months;
• 7. Female subjects with fertility should undergo a urine or serum pregnancy test within 72 hours prior to the first study drug administration and are shown to be negative ,and willing to be 3 months after the last dose of SHR-1210 injection during the trial period. The effective method was used for contraception (from the control group to 180 days after the last administration). For male subjects whose partners are women of childbearing age, effective methods should be used during the test period and within 3 months after the last administration of SHR-1210 injection (control group to 180 days after the last administration);
• 8. Patients were voluntarily enrolled in the study and signed an informed consent form (ICF) with good adherence and follow-up.

Exclusion Criteria

• 1. The patient has any active autoimmune disease or a history of autoimmune disease;
• 2.The patient is using immunosuppressive agents or systemic hormonal therapy for immunosuppression purposes (dose>10 mg / day of prednisone or other therapeutic hormones);
• 3.Interstitial pneumonia ;
• 4.Severe allergic reactions to other monoclonal antibodies ;
• 5.Suffering from high blood pressure and not being well controlled by antihypertensive medication (systolic blood pressure≥140 mmHg or diastolic blood pressure≥90 mmHg) ;
• 6.Have clinical symptoms or disease that are not well controlled ;
• 7.Abnormal coagulation function (INR>2.0, PT>16s), bleeding tendency or receiving thrombolysis or anticoagulant therapy, allowing prophylactic use of low-dose aspirin, low molecular weight heparin;
• 8.There was significant coughing blood in the first 2 months before enrollment, or daily hemoptysis amounted to 2.5ml or more;
• 9.Significant clinically significant bleeding symptoms or a clear tendency to hemorrhage during the first 3 months of randomization;
• 10.Urinary routine suggests urinary protein≥ ++ and confirmed 24-hour urine protein> 1.0 g ;
• 11.The patient has active infection, unexplained fever within 3 days before administration, ≥38.5 °C, or baseline white blood cell count>15×109/L;
• 12.The patient has previously received other PD-1 antibody therapy or other immunotherapy against PD-1/PD-L1;
• 13.Other patients considered by the treating physician not suitable for inclusion .

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Sichuan Cancer Hospital and Research Institute

OTHER

Sponsor Role: lead

Responsible Party

Juan LI, MD

MD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Juan Li, MD

Role: PRINCIPAL_INVESTIGATOR

Sichuan Cancer Hospital and Research Institute

Locations

Sichuan Cancer Hospital

Chengdu, Sichuan, China

Countries

China

Central Contacts

Juan Li, MD

Role: CONTACT

dr.lijuan@gmail.com

+8613880276636

Facility Contacts

Juan Li, MD

Role: primary

dr.lijuan@gmail.com

+8613880276636

Other Identifiers

HR-SHR-NSCLC201906

Identifier Type: -

Identifier Source: org_study_id